Vermeijden Harmen D, Holuba Kurt, Yang Xiuyi A, O'Brien Robert, van der List Jelle P, DiFelice Gregory S
Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, New York, USA.
Department of Orthopaedic Surgery, Spaarne Gasthuis Hospital, Hoofddorp, the Netherlands.
Orthop J Sports Med. 2023 Sep 29;11(9):23259671231187442. doi: 10.1177/23259671231187442. eCollection 2023 Sep.
Anterior cruciate ligament (ACL) reconstruction (ACLR) is associated with postoperative pain and necessitates using perioperative nerve blocks and multimodal analgesic plans.
To assess postoperative pain and daily opioid use after ACL repair versus ACLR and to assess whether ACL repair could be performed successfully without using long-acting nerve blocks.
Cohort study; Level of evidence, 2.
All eligible patients who underwent ACL surgery between 2019 and 2022 were prospectively enrolled. Patients were treated with primary repair if proximal tears with sufficient tissue quality were present; otherwise, they underwent single-bundle ACLR with either hamstring tendon or quadriceps tendon autograft. The patients were divided into 3 groups: ACLR with adductor canal nerve block (up to 20 mL of 0.25% bupivacaine with 2 mg dexamethasone), primary repair with nerve block, and primary repair without nerve block. Pain visual analog scale and number of opioids used were recorded during the first 14 postoperative days (PODs). Furthermore, patients completed the Quality of Recovery-15 (QoR-15) survey, and range of motion was assessed. Group differences were compared using Mann-Whitney test and chi-square test.
Seventy-eight patients were included: 30 (39%) underwent ACLR, 19 (24%) ACL repair with nerve block, and 29 (37%) ACL repair without nerve block. Overall, the ACL repair group used significantly fewer opioids than the ACLR group on POD 1 (1 vs 3, = .027) and POD 2 (1 vs 3, = .014) while also using fewer opioids in total (3 vs 8, = .038). This difference was even more marked when only analyzing those patients who received postoperative nerve blocks (1 vs 8, = .029). Repair patients had significantly higher QoR-15 scores throughout the first postoperative week, and they had greater range of motion (all < .05). There were no significant differences in pain scores, opioid usage, or QoR-15 scores between patients who underwent repair with versus without nerve block.
The ACL repair group experienced less postoperative pain during the first 2 weeks after surgery and used significantly fewer opioids than the ACLR group. Furthermore, they had improved knee function and higher recovery quality than patients who underwent ACLR during the initial postoperative period. Postoperative nerve blocks may not be necessary after ACL repair.
前交叉韧带(ACL)重建术(ACLR)与术后疼痛相关,需要使用围手术期神经阻滞和多模式镇痛方案。
评估ACL修复术与ACLR术后的疼痛情况及每日阿片类药物使用量,并评估在不使用长效神经阻滞的情况下,ACL修复术是否能成功实施。
队列研究;证据等级,2级。
前瞻性纳入2019年至2022年间接受ACL手术的所有符合条件的患者。若存在组织质量足够的近端撕裂,则对患者进行一期修复;否则,他们接受单束ACLR,采用腘绳肌腱或股四头肌腱自体移植。患者分为3组:采用收肌管神经阻滞的ACLR组(最多20 mL 0.25%布比卡因加2 mg地塞米松)、采用神经阻滞的一期修复组和不采用神经阻滞的一期修复组。在术后的前14天(POD)记录疼痛视觉模拟量表评分和使用的阿片类药物数量。此外,患者完成术后恢复质量-15(QoR-15)调查,并评估活动范围。使用Mann-Whitney检验和卡方检验比较组间差异。
共纳入78例患者:30例(39%)接受ACLR,19例(24%)接受带神经阻滞的ACL修复术,29例(37%)接受不带神经阻滞的ACL修复术。总体而言,ACL修复组在术后第1天(1 vs 3,P = .027)和第2天(1 vs 3,P = .014)使用的阿片类药物明显少于ACLR组,且总共使用的阿片类药物也较少(3 vs 8,P = .038)。仅分析那些接受术后神经阻滞的患者时,这种差异更为明显(1 vs 8,P = .029)。修复组患者在术后第一周的QoR-15评分显著更高,且活动范围更大(均P < .05)。接受神经阻滞与未接受神经阻滞的修复患者在疼痛评分、阿片类药物使用量或QoR-15评分方面无显著差异。
ACL修复组在术后前2周的术后疼痛较轻,使用的阿片类药物明显少于ACLR组。此外,与ACLR患者相比,他们在术后初期膝关节功能得到改善,恢复质量更高。ACL修复术后可能无需进行术后神经阻滞。